More than a month after failing its Friedrich’s ataxia trial, PTC Therapeutics’ vatiquinone has again missed its primary endpoint, this time in a mitochondrial disease-associated seizures study.
https://www.pharmalive.com/wp-content/uploads/2022/08/brain-scans.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-06-30 09:45:442023-06-30 10:08:21PTC’s vatiquinone fails second trial in as many months
